Navigation Links
Vaccine first to show improved survival rates for metastatic melanoma
Date:6/3/2011

(CHICAGO) For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival.

The findings of the study were published in the June 2 issue of New England Journal of Medicine. This marks the first vaccine study in the disease and one of the first in all cancers to show clinical benefit in a randomized Phase III clinical trial.

"This is the first time that a vaccine has shown benefit in the treatment of patients with metastatic melanoma. The trial is an early example of success with a cancer vaccine," said Dr. Howard Kaufman, director for the Rush University Cancer Center and study co-investigator.

"If we can use the body's own defense system to attack tumor cells, we provide a mechanism for ridding the body of cancer without destroying healthy tissue," said Kaufman, who is also an associate dean of Rush Medical College and a professor in the departments of general surgery, internal medicine and immunology and microbiology at Rush University.

Therapeutic cancer vaccines, unlike typical vaccines that prevent infections, are meant to jump-start the immune system to help it battle existing tumors.

Rush was one of 21 centers in the U.S. participating in the trial. Researchers randomly assigned 185 patients with metastatic melanoma to either a combination of the peptide vaccine, which is a small portion of protein that is present on the surface of the melanoma cancer cells, and Interleukin-2, a drug that activates the immune system, or a high dose of Interleukin-2 alone.

The peptide vaccine, known as gp100:209-217 (200M), works by stimulating the patient's T-cells, which is known for controlling immune responses. The injection primes the immune system to recognize the protein and activates the body's cytotoxic T-cells to recognize the antigens on the surface of the cancerous tumor. The T-cells then secrete enzymes to seek out and destroy the tumor cell's membrane.

The immune-boosting drug, Interleukin-2, enhances the vaccine's effectiveness by stimulating the production of lymphocytes, a type of white blood cell that circulates throughout the body. More circulating lymphocytes means there are more cells available to do the job the vaccine has educated them to do.

Ninety-four patients in the Interleukin-2 arm of the study were enrolled and 93 were treated and evaluated for response. In the Interleukin-2 and peptide vaccine combination arm of the study, 91 were enrolled, 86 were treated and 85 were evaluated for response.

About 16 percent of study participants given the vaccine and Interleukin-2 combination saw tumors shrink by 50 percent or more, compared to 6 percent given Interleukin-2 alone.

Those in the vaccine and drug combination group also had slightly longer progression-free survival rates of 2.2 months compared to 1.6 months, which means those participants had more time in which the tumor did not grow.

Patients given the combination also lived an average of nearly seven months longer than those only give Interleukin-2 -- 17.8 months longer compared to 11.1 months.

In order for this vaccine to work, patients had to have a particular tissue type, called HLA-A2, which is present in about half of whites.

According to the American Cancer Society, melanoma has one of the fastest growing incident rates of all cancers. The five-year survival rate for melanoma patients is less than 10 percent.

Interleukin-2 is already FDA-approved to treat metastatic melanoma and kidney cancer.

The next step is to improve the vaccine's efficacy. Researchers hope to improve upon the study's findings by combining the vaccine with other immune-stimulatory agents such as adjuvants, other cytokines and antibodies that further activate the immune cells.

"This is one of the first positive, randomized vaccine trials in cancer and the findings represent a significant step forward for treatment of advanced melanoma," said Kaufman.

The vaccine, if eventually approved by the FDA, would be relatively inexpensive because it is based on a protein that's present in most melanoma cancers, whereas other vaccines have had to be created for each individual patient.


'/>"/>

Contact: Deb Song
deb_song@rush.edu
312-942-0588
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times
2. ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
3. Therapeutic melanoma vaccine improves response rate, progression-free survival
4. Melanoma Vaccine Shows Promise in Trial
5. Vaccine increases disease-free survival for follicular lymphoma patients
6. Black Americans With Lupus Have Better Response to Flu Vaccine
7. African-Americans with SLE more responsive to flu vaccine than patients of European descent
8. Toward a vaccine for methamphetamine abuse
9. Model developed to improve combination vaccine accessibility worldwide
10. Rino Rappuoli honored for his work in vaccines and vaccinology
11. Insight into HIV immunity may lead to vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... VA (PRWEB) , ... May 24, 2016 , ... Controlling ... smarter - with the launch of the Aquanta Water Heater Controller , a ... smart phone or web-enabled device. As the Nest thermostat does for HVAC systems, ...
(Date:5/24/2016)... WI (PRWEB) , ... May 24, 2016 , ... ... In Milwaukee , Out patient Services To Begin In June , Aloria Health, ... pleased to announce the opening of Aloria Milwaukee, its first treatment facility for ...
(Date:5/24/2016)... NJ (PRWEB) , ... May 24, 2016 , ... The ... that’s causing the problem. A common injury that’s often misunderstood, whiplash should be swiftly ... MD, a Harvard-trained, orthopedic spine surgeon at Atlantic Spine Center . , ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... successful implementation of protocols designed to reduce bleeding complications from percutaneous coronary intervention ... Angiography and Interventions (SCAI) in Orlando, FL, document a 40% reduction in risk-adjusted ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Essette Dashboard, its highly anticipated, web-based software module. The cutting-edge feature provides ... “secret sauce”? Integration with Izenda’s self-service business intelligence solution and its analytics ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today ... programs. The hands-on learning experience is a 12-week summer ... Fellowship and Internship programs bring ... and interns are provided optional housing free of charge ... at the Riverfront Residence Hall to foster communication and ...
(Date:5/23/2016)... May 23, 2016 Non-invasive diagnostic ... of multiple diseases; ,Technology to be presented at Yissum’s ... Yissum Research Development Company of the Hebrew University of ... research agreement with Aurum Ventures MKI, the technology investment arm ... a new diagnostic approach for early detection of multiple ...
(Date:5/22/2016)... May 23, 2016 DS ... anti-fibrotic and anti-inflammatory compound DS102 in chronic obstructive ... non-alcoholic steatohepatitis (NASH) patients. Recent DS ... in lung tissue and has bronchodilatory, anti-inflammatory and ... administration. The Company will publish further detail on ...
Breaking Medicine Technology: